Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
AbstrakAnemia merupakan salah satu efek samping yang paling sering dialami pasien kanker yang diterapi dengan cisplatin dosis tinggi. Penelitian ini bertujuan untuk mengamati perkembangan anemia dan menentukan faktor-faktor yang berpengaruh terhadap anemia pada pasien yang diterapi cisplatin. Dilakukan pengumpulan data pada pasien kanker kepala dan leher yang menjalani kemoterapi berbasis cisplatin antara Desember 2002 hingga Desember 2005. Insidensi dan faktor risiko anemia dianalisis dengan mencakup faktor usia, jenis kelamin, kadar Hb awal, klirens kreatinin awal, dan metastasis jauh. Stratifikasi menurut usia dan jenis kelamin dilakukan terhadap kadar Hb awal dan CrCl awal. Analisis multivariat digunakan untuk mengidentifikasi prediktor independen anemia. Dari 86 pasien, 26 (30,2%) mengalami anemia, ditandai kadar hemoglobin < 11 g/dL. Kadar hemoglobin turun secara signifikan setelah siklus pertama, dan terus menurun. Usia > 55 tahun (RR = 2.2, 95% CI, 1.2-4.0), jenis kelamin perempuan (RR = 2.0, 95% CI, 1.2-3.8), kadar Hb awal ≤ 13 g/dL (RR = 4.2, 95% CI, 1.9-9.4) dan CrCl awal < 50 mL/menit (RR = 2.9, 95% CI, 1.7-5.1) berkorelasi dengan insidensi anemia (P < 0.05). Pada analisis multivariat, kadar hemoglobin awal dan klirens kreatinin awal merupakan faktor risiko independen anemia. Akan tetapi, terdapat efek perancu pada klirens kreatinin awal pada stratifikasi menurut usia (aRR = 2.2, 95% CI, 1.1-4.7). Kadar hemoglobin awal merupakan prediktor terkuat dari anemia. Kadar hemoglobin awal ≤ 13 g/dL ke bawah dan klirens kreatinin awal < 50 g/dL merupakan prediktor independen anemia akibat cisplatin, sehingga keduanya bernilai penting terhadap upaya prevensi anemia. (Med J Indones 2008; 17: 248-54) AbstractsCisplatin is well-known for its effectiveness against cancer, as well as its toxicity to human tissues. Of several documented side effects, anemia was reported to have significant association with decreased quality of life. This study was conducted to investigate development of cisplatin-induced anemia, and to identify independent factors contributing to anemia. Clinical data from head and neck cancer patients treated with high-dose cisplatin between December 2002 and December 2005 were obtained in this study. Incidence and risk factors of anemia were assessed in a model including age, sex, baseline hemoglobin level, baseline creatinine clearance, and occurrence of distant metastases. Multivariate logistic regression was used to define independent predictors of anemia. Among 86 eligible patients, 26 (30.2%) developed anemia, defined as Hb level lower than 11 g/dL. Age > 55 years old (RR = 2.2, 95% CI,, female sex (RR = 2.0, 95% CI, baseline Hb ≤ 13 g/dL (RR = 4.2, 95% CI,) and baseline CrCl < 50 mL/min (RR = 2.9, 95% CI, 1.7-5.1) were significantly correlated with incidence of anemia (P < 0.05). In multivariate analysis, baseline Hb and baseline CrCl were identified as independent risk factors for anemia. However, considerable confounding was observed in baseline CrCl after stratified by age (aRR = 2.2,...
AbstrakAnemia merupakan salah satu efek samping yang paling sering dialami pasien kanker yang diterapi dengan cisplatin dosis tinggi. Penelitian ini bertujuan untuk mengamati perkembangan anemia dan menentukan faktor-faktor yang berpengaruh terhadap anemia pada pasien yang diterapi cisplatin. Dilakukan pengumpulan data pada pasien kanker kepala dan leher yang menjalani kemoterapi berbasis cisplatin antara Desember 2002 hingga Desember 2005. Insidensi dan faktor risiko anemia dianalisis dengan mencakup faktor usia, jenis kelamin, kadar Hb awal, klirens kreatinin awal, dan metastasis jauh. Stratifikasi menurut usia dan jenis kelamin dilakukan terhadap kadar Hb awal dan CrCl awal. Analisis multivariat digunakan untuk mengidentifikasi prediktor independen anemia. Dari 86 pasien, 26 (30,2%) mengalami anemia, ditandai kadar hemoglobin < 11 g/dL. Kadar hemoglobin turun secara signifikan setelah siklus pertama, dan terus menurun. Usia > 55 tahun (RR = 2.2, 95% CI, 1.2-4.0), jenis kelamin perempuan (RR = 2.0, 95% CI, 1.2-3.8), kadar Hb awal ≤ 13 g/dL (RR = 4.2, 95% CI, 1.9-9.4) dan CrCl awal < 50 mL/menit (RR = 2.9, 95% CI, 1.7-5.1) berkorelasi dengan insidensi anemia (P < 0.05). Pada analisis multivariat, kadar hemoglobin awal dan klirens kreatinin awal merupakan faktor risiko independen anemia. Akan tetapi, terdapat efek perancu pada klirens kreatinin awal pada stratifikasi menurut usia (aRR = 2.2, 95% CI, 1.1-4.7). Kadar hemoglobin awal merupakan prediktor terkuat dari anemia. Kadar hemoglobin awal ≤ 13 g/dL ke bawah dan klirens kreatinin awal < 50 g/dL merupakan prediktor independen anemia akibat cisplatin, sehingga keduanya bernilai penting terhadap upaya prevensi anemia. (Med J Indones 2008; 17: 248-54) AbstractsCisplatin is well-known for its effectiveness against cancer, as well as its toxicity to human tissues. Of several documented side effects, anemia was reported to have significant association with decreased quality of life. This study was conducted to investigate development of cisplatin-induced anemia, and to identify independent factors contributing to anemia. Clinical data from head and neck cancer patients treated with high-dose cisplatin between December 2002 and December 2005 were obtained in this study. Incidence and risk factors of anemia were assessed in a model including age, sex, baseline hemoglobin level, baseline creatinine clearance, and occurrence of distant metastases. Multivariate logistic regression was used to define independent predictors of anemia. Among 86 eligible patients, 26 (30.2%) developed anemia, defined as Hb level lower than 11 g/dL. Age > 55 years old (RR = 2.2, 95% CI,, female sex (RR = 2.0, 95% CI, baseline Hb ≤ 13 g/dL (RR = 4.2, 95% CI,) and baseline CrCl < 50 mL/min (RR = 2.9, 95% CI, 1.7-5.1) were significantly correlated with incidence of anemia (P < 0.05). In multivariate analysis, baseline Hb and baseline CrCl were identified as independent risk factors for anemia. However, considerable confounding was observed in baseline CrCl after stratified by age (aRR = 2.2,...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.